1 Presentation on Measles Group 1
-
Upload
draditya21 -
Category
Documents
-
view
216 -
download
0
Transcript of 1 Presentation on Measles Group 1
-
8/3/2019 1 Presentation on Measles Group 1
1/27
Measles SurveillanceMeasles Surveillance
Group 1
1. Dr. Binay Kr.
2. Dr. Om Prakash3. Dr. Parvez
4. Dr. O Ramesh Singh
5. Dr. Sunep
6. Dr. AdityaPGDPHM- 12 IIPHD
-
8/3/2019 1 Presentation on Measles Group 1
2/27
OUTLINES
y Background
y Case definitions
y Laboratory criteria for diagnosis
y
Type of surveillancey Selection & training
y Flow chart for distribution of forms &
kitsy Data flow chart
y Action
-
8/3/2019 1 Presentation on Measles Group 1
3/27
-
8/3/2019 1 Presentation on Measles Group 1
4/27
In 1998 it is estimated that there were
approximately one million deaths from measles
MORTALITY
PRE-VACCINE ERA
1998
MORBIDITY
0
1
2
3
4
5
6
7
Millions
0
20
40
60
80
100
120
Millions
PRE-VACCINE ERA
1998
WHO unpublished data
63% 83%
In other words,
the measles virus killed ..
2,410 children each day
100 children each hour
. 150 children died
during the time elapsed
by the end of this
presentation
-
8/3/2019 1 Presentation on Measles Group 1
5/27
Diphtheria
0.2%
Pertussis
16%
Neonatal
Tetanus
12%
Yellow Fever2%
Measles
48%(777,000
Deaths)
Hib
22%
Causes of 1.6 million vaccineCauses of 1.6 million vaccine--preventable deathspreventable deathsamongamong childrenchildren, 2000, 2000
Source: WHO/IP
MEASLES: A leading cause of childhood deaths
-
8/3/2019 1 Presentation on Measles Group 1
6/27
Case DefinitionsCase DefinitionsFor sub CentersFor sub Centers
A child with -
generalized maculopapular rash,
fever, and
with one or more of the following:
cough,
coryza - sneezing, nasal congestion,
and nasal discharge
-
8/3/2019 1 Presentation on Measles Group 1
7/27
Maculopapular
RashFever +
Cough OR
Coryza (runny nose) OR
Conjunctivitis (red eyes)+
uspected Measlesuspected Measles
linicallinical Case DefinitionCase Definition
OR
Clinician
Suspects
Measles
-
8/3/2019 1 Presentation on Measles Group 1
8/27
Case DefinitionsCase DefinitionsFor MOs at CHC/PHC/DHFor MOs at CHC/PHC/DH
Measles is characterized by a
generalized maculopapular rash,
fever, and
With one or more of the following:
cough,
coryza
Conjunctivitis,photophobia,
Kopliks spots - bluish-white specks on arose-red background appearing on thebuccal mucosa usually opposite themolars.
-
8/3/2019 1 Presentation on Measles Group 1
9/27
-
8/3/2019 1 Presentation on Measles Group 1
10/27
Measles Case Definition To AssistMeasles Case Definition To Assist
Communities inCommunities in
Notifying Health FacilitiesNotifying Health Facilities
ANY PERSONwith
FEVER and RASH
-
8/3/2019 1 Presentation on Measles Group 1
11/27
Key Information to Collect on SuspectedKey Information to Collect on Suspected
Measles CasesMeasles Cases
Person
Age
Vaccination status
Lab data
Time
Date of rash onset
PlaceResidence at onset
Potential exposures (places, persons)
-
8/3/2019 1 Presentation on Measles Group 1
12/27
Improved RoutineImproved Routine
ImmunizationImmunization
StrengthenStrengthen
measles surveillancemeasles surveillance
SupplementalSupplemental
measles immunizationmeasles immunization
Improved caseImproved case
managementmanagement
Vitamin AVitamin A
supplementationsupplementation
Measles Mortality Reduction StrategiesMeasles Mortality Reduction Strategies
-
8/3/2019 1 Presentation on Measles Group 1
13/27
LaboratoryLaboratory Criteria for DiagnosisCriteria for Diagnosis
Significant rise in serum measles
immunoglobulin G (IgG)antibody level by
any standard serologic assay
Positive serologic test for measlesimmunoglobulin M (IgM)antibody.
-
8/3/2019 1 Presentation on Measles Group 1
14/27
Rash Illness
Rubella
Roseola Infantum
Other Viral Exanthems
Meningococcemia
Mononucleosis
Toxoplasmosis
Dengue
Kawasaki
Measles
Scarlet Fever
-
8/3/2019 1 Presentation on Measles Group 1
15/27
Type of surveillance for measlesType of surveillance for measles
Active surveillance
High no of case
Highly infectious
High morbidity and mortality
Easily preventable
Main objective is sustainable reduction in morbidity& mortality due to measles.
-
8/3/2019 1 Presentation on Measles Group 1
16/27
Responsible persons forreportingy Reporting unit
Medical Officers
Hospitals: inpatient and outpatient
clinics.
Medical Officers/SN/ANM/Vaccinators
CHC/PHC/SC
y Information unit
Private clinics/hospitals/nursing homes
-
8/3/2019 1 Presentation on Measles Group 1
17/27
Selection and training
Medical Officers at District level, by DIO
MOs and Private practitioners at district level
will be trained at the district level
All the ANM, Field staffs and ASHAs- to be
trained at CHC/PHC level
All Private practitioners, at block level andbelow, to be trained at CHC/PHC level
-
8/3/2019 1 Presentation on Measles Group 1
18/27
What should health care provider do whenWhat should health care provider do when
she/he suspects measles?she/he suspects measles?
y Notify case
y Complete case investigation form
y Collect blood sample
y Manage case (Vitamin A, supportivetreatment, etc.)
-
8/3/2019 1 Presentation on Measles Group 1
19/27
-
8/3/2019 1 Presentation on Measles Group 1
20/27
Flow chart for forms & kitsFlow chart for forms & kits
CMO
DIO
DH/DS
MO i/c -CHC/PHC/SC
Privatehosp/clinic
ASHA
-
8/3/2019 1 Presentation on Measles Group 1
21/27
FLOW OF DATA
State
District CMO
District
Immunization
Officer
CHCMO & SN
District
Hospitals
MS/DS
PHCMO
Private
Hospitals/
Nursing
homes/Quacks
MO & SN
Sub Centre
ANM
ASHA
-
8/3/2019 1 Presentation on Measles Group 1
22/27
tools for collection of data andtools for collection of data and
samplessamples
-
8/3/2019 1 Presentation on Measles Group 1
23/27
Action/ Implement
Activities will includey strengthening routine immunization
y raising awareness of vaccination
y effective case management
The response should take place before an
outbreak occurs.
In case of a confirmed measles outbreak, DIO will form
an outbreak response team at district level consisting of a
Medical Officer, Microbiologist & epidemiologist.
-
8/3/2019 1 Presentation on Measles Group 1
24/27
Outbreak ResponseOutbreak Response
1. Case notification
2. Case verification
3. Field investigation4. Management
5. Post outbreak activities
-
8/3/2019 1 Presentation on Measles Group 1
25/27
-
8/3/2019 1 Presentation on Measles Group 1
26/27
-
8/3/2019 1 Presentation on Measles Group 1
27/27